HEADER CHAPERONE 05-JUN-12 4AWO TITLE COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED INHIBITORS COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: ATPASE DOMAIN, RESIDUES 9-236; COMPND 5 SYNONYM: HSP90, HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA COMPND 6 ANTIGEN NY-REN-38; COMPND 7 EC: 3.6.4.10; COMPND 8 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS CHAPERONE EXPDTA X-RAY DIFFRACTION AUTHOR J.C.LOUGHEED,T.J.STOUT REVDAT 1 29-AUG-12 4AWO 0 JRNL AUTH J.BUSSENIUS,C.M.BLAZEY,N.AAY,N.K.ANAND,A.ARCALAS,T.BAIK, JRNL AUTH 2 O.J.BOWLES,C.A.BUHR,S.COSTANZO,J.K.CURTIS,S.C.DEFINA, JRNL AUTH 3 L.DUBENKO,T.S.HEUER,P.HUANG,C.JAEGER,A.JOSHI,A.R.KENNEDY, JRNL AUTH 4 A.I.KIM,K.LARA,J.LEE,J.LI,J.C.LOUGHEED,S.MA,S.MALEK, JRNL AUTH 5 J.C.MANALO,J.F.MARTINI,G.MCGRATH,M.NICOLL,J.M.NUSS,M.PACK, JRNL AUTH 6 C.J.PETO,T.H.TSANG,L.WANG,S.W.WOMBLE,M.YAKES,W.ZHANG, JRNL AUTH 7 K.D.RICE JRNL TITL DISCOVERY OF XL888: A NOVEL TROPANE-DERIVED SMALL MOLECULE JRNL TITL 2 INHIBITOR OF HSP90. JRNL REF BIOORG.MED.CHEM.LETT. V. 22 5396 2012 JRNL REFN ISSN 0960-894X JRNL PMID 22877636 JRNL DOI 10.1016/J.BMCL.2012.07.052 REMARK 2 REMARK 2 RESOLUTION. 1.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.2.0019 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 54.07 REMARK 3 DATA CUTOFF (SIGMA(F)) : NONE REMARK 3 COMPLETENESS FOR RANGE (%) : 94.70 REMARK 3 NUMBER OF REFLECTIONS : 49527 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.21504 REMARK 3 R VALUE (WORKING SET) : 0.21303 REMARK 3 FREE R VALUE : 0.25111 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.0 REMARK 3 FREE R VALUE TEST SET COUNT : 2628 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.700 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.744 REMARK 3 REFLECTION IN BIN (WORKING SET) : 3654 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 94.47 REMARK 3 BIN R VALUE (WORKING SET) : 0.350 REMARK 3 BIN FREE R VALUE SET COUNT : 187 REMARK 3 BIN FREE R VALUE : 0.360 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 3233 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 74 REMARK 3 SOLVENT ATOMS : 272 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 28.256 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.37 REMARK 3 B22 (A**2) : -0.52 REMARK 3 B33 (A**2) : 0.49 REMARK 3 B12 (A**2) : 0.69 REMARK 3 B13 (A**2) : 0.95 REMARK 3 B23 (A**2) : -0.27 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.120 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.119 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.088 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 2.613 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.953 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.932 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 3365 ; 0.021 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 4543 ; 1.875 ; 1.986 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 405 ; 6.233 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 148 ;36.995 ;25.135 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 616 ;15.024 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 14 ;22.924 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 521 ; 0.221 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 2472 ; 0.010 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): 1575 ; 0.211 ; 0.200 REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): 2308 ; 0.306 ; 0.200 REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): 204 ; 0.133 ; 0.200 REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): 44 ; 0.225 ; 0.200 REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): 5 ; 0.136 ; 0.200 REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2121 ; 1.328 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 3270 ; 1.935 ; 2.000 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 1456 ; 2.895 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 1267 ; 4.138 ; 4.500 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 4AWO COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 06-JUN-12. REMARK 100 THE PDBE ID CODE IS EBI-52770. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 05-JUL-07 REMARK 200 TEMPERATURE (KELVIN) : 93.2 REMARK 200 PH : 8.0 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97946 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 52156 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.70 REMARK 200 RESOLUTION RANGE LOW (A) : 41.51 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 94.6 REMARK 200 DATA REDUNDANCY : 1.98 REMARK 200 R MERGE (I) : 0.14 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 11.60 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.90 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.4 REMARK 200 DATA REDUNDANCY IN SHELL : 1.99 REMARK 200 R MERGE FOR SHELL (I) : 0.53 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.69 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: IN-HOUSE APO STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 51.92 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.58 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1750 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 18620 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.6 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 7 REMARK 465 SER A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 MET A 12 REMARK 465 GLU A 13 REMARK 465 GLU A 14 REMARK 465 GLU A 15 REMARK 465 GLU A 16 REMARK 465 ALA A 124 REMARK 465 GLY A 125 REMARK 465 ALA A 126 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 465 GLY B 7 REMARK 465 SER B 8 REMARK 465 ASP B 9 REMARK 465 GLN B 10 REMARK 465 PRO B 11 REMARK 465 MET B 12 REMARK 465 GLU B 13 REMARK 465 GLU B 14 REMARK 465 GLU B 15 REMARK 465 GLU B 16 REMARK 465 ALA B 124 REMARK 465 GLY B 125 REMARK 465 ALA B 126 REMARK 465 LYS B 224 REMARK 465 GLU B 225 REMARK 465 ARG B 226 REMARK 465 ASP B 227 REMARK 465 LYS B 228 REMARK 465 GLU B 229 REMARK 465 VAL B 230 REMARK 465 SER B 231 REMARK 465 ASP B 232 REMARK 465 ASP B 233 REMARK 465 GLU B 234 REMARK 465 ALA B 235 REMARK 465 GLU B 236 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG A 60 NE - CZ - NH1 ANGL. DEV. = 4.8 DEGREES REMARK 500 ARG A 60 NE - CZ - NH2 ANGL. DEV. = -3.6 DEGREES REMARK 500 PHE B 221 CB - CA - C ANGL. DEV. = -19.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 40 49.91 -85.93 REMARK 500 ASN A 106 166.69 75.00 REMARK 500 ALA A 166 -142.41 64.38 REMARK 500 ASN B 40 57.10 -93.89 REMARK 500 ASN B 106 170.06 75.55 REMARK 500 PHE B 134 10.25 -67.09 REMARK 500 ALA B 166 -151.25 65.90 REMARK 500 ARG B 182 141.38 -170.11 REMARK 500 VAL B 222 131.24 -38.70 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 FOR AMINO ACIDS AND C1'--O4'--N1(N9)--C2' FOR REMARK 500 NUCLEIC ACIDS OR EQUIVALENT ANGLE REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 VAL A 222 22.8 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 99B A1225 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 99B B1225 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY REMARK 900 -BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL REMARK 900 )-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6YLAMINE REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 REMARK 900 -TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN REMARK 900 -6-YLAMINE REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR REMARK 900 BINDING TO HSP90 ISOFORMS REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING REMARK 900 DOMAIN REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN REMARK 900 PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN REMARK 900 LIGASE REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- REMARK 900 PYRAZOL-3-YL)-BENZENE-1,2-DIOL REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- REMARK 900 4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID REMARK 900 ETHYLAMIDE REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- REMARK 900 METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3- REMARK 900 YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H64 REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H71 REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE REMARK 900 FRAGMENT REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO REMARK 900 AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC REMARK 900 PYRAZOLE, ISOXAZOLE AMIDE ANALOGS REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHX RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJG RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJJ RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XK2 RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YE2 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE3 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE4 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE5 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE6 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE7 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE8 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE9 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEA RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEB RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEC RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YED RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEE RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEF RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEG RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEH RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEI RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEJ RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YI0 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI5 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI6 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI7 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YJW RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YJX RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK2 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK9 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKB RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKC RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKE RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKI RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKJ RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 4AIF RELATED DB: PDB REMARK 900 AIP TPR DOMAIN IN COMPLEX WITH HUMAN HSP90 PEPTIDE REMARK 900 RELATED ID: 4AWP RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED REMARK 900 INHIBITORS REMARK 900 RELATED ID: 4AWQ RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED REMARK 900 INHIBITORS DBREF 4AWO A 9 236 UNP P07900 HS90A_HUMAN 9 236 DBREF 4AWO B 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 4AWO GLY A 7 UNP P07900 EXPRESSION TAG SEQADV 4AWO SER A 8 UNP P07900 EXPRESSION TAG SEQADV 4AWO GLY B 7 UNP P07900 EXPRESSION TAG SEQADV 4AWO SER B 8 UNP P07900 EXPRESSION TAG SEQRES 1 A 230 GLY SER ASP GLN PRO MET GLU GLU GLU GLU VAL GLU THR SEQRES 2 A 230 PHE ALA PHE GLN ALA GLU ILE ALA GLN LEU MET SER LEU SEQRES 3 A 230 ILE ILE ASN THR PHE TYR SER ASN LYS GLU ILE PHE LEU SEQRES 4 A 230 ARG GLU LEU ILE SER ASN SER SER ASP ALA LEU ASP LYS SEQRES 5 A 230 ILE ARG TYR GLU SER LEU THR ASP PRO SER LYS LEU ASP SEQRES 6 A 230 SER GLY LYS GLU LEU HIS ILE ASN LEU ILE PRO ASN LYS SEQRES 7 A 230 GLN ASP ARG THR LEU THR ILE VAL ASP THR GLY ILE GLY SEQRES 8 A 230 MET THR LYS ALA ASP LEU ILE ASN ASN LEU GLY THR ILE SEQRES 9 A 230 ALA LYS SER GLY THR LYS ALA PHE MET GLU ALA LEU GLN SEQRES 10 A 230 ALA GLY ALA ASP ILE SER MET ILE GLY GLN PHE GLY VAL SEQRES 11 A 230 GLY PHE TYR SER ALA TYR LEU VAL ALA GLU LYS VAL THR SEQRES 12 A 230 VAL ILE THR LYS HIS ASN ASP ASP GLU GLN TYR ALA TRP SEQRES 13 A 230 GLU SER SER ALA GLY GLY SER PHE THR VAL ARG THR ASP SEQRES 14 A 230 THR GLY GLU PRO MET GLY ARG GLY THR LYS VAL ILE LEU SEQRES 15 A 230 HIS LEU LYS GLU ASP GLN THR GLU TYR LEU GLU GLU ARG SEQRES 16 A 230 ARG ILE LYS GLU ILE VAL LYS LYS HIS SER GLN PHE ILE SEQRES 17 A 230 GLY TYR PRO ILE THR LEU PHE VAL GLU LYS GLU ARG ASP SEQRES 18 A 230 LYS GLU VAL SER ASP ASP GLU ALA GLU SEQRES 1 B 230 GLY SER ASP GLN PRO MET GLU GLU GLU GLU VAL GLU THR SEQRES 2 B 230 PHE ALA PHE GLN ALA GLU ILE ALA GLN LEU MET SER LEU SEQRES 3 B 230 ILE ILE ASN THR PHE TYR SER ASN LYS GLU ILE PHE LEU SEQRES 4 B 230 ARG GLU LEU ILE SER ASN SER SER ASP ALA LEU ASP LYS SEQRES 5 B 230 ILE ARG TYR GLU SER LEU THR ASP PRO SER LYS LEU ASP SEQRES 6 B 230 SER GLY LYS GLU LEU HIS ILE ASN LEU ILE PRO ASN LYS SEQRES 7 B 230 GLN ASP ARG THR LEU THR ILE VAL ASP THR GLY ILE GLY SEQRES 8 B 230 MET THR LYS ALA ASP LEU ILE ASN ASN LEU GLY THR ILE SEQRES 9 B 230 ALA LYS SER GLY THR LYS ALA PHE MET GLU ALA LEU GLN SEQRES 10 B 230 ALA GLY ALA ASP ILE SER MET ILE GLY GLN PHE GLY VAL SEQRES 11 B 230 GLY PHE TYR SER ALA TYR LEU VAL ALA GLU LYS VAL THR SEQRES 12 B 230 VAL ILE THR LYS HIS ASN ASP ASP GLU GLN TYR ALA TRP SEQRES 13 B 230 GLU SER SER ALA GLY GLY SER PHE THR VAL ARG THR ASP SEQRES 14 B 230 THR GLY GLU PRO MET GLY ARG GLY THR LYS VAL ILE LEU SEQRES 15 B 230 HIS LEU LYS GLU ASP GLN THR GLU TYR LEU GLU GLU ARG SEQRES 16 B 230 ARG ILE LYS GLU ILE VAL LYS LYS HIS SER GLN PHE ILE SEQRES 17 B 230 GLY TYR PRO ILE THR LEU PHE VAL GLU LYS GLU ARG ASP SEQRES 18 B 230 LYS GLU VAL SER ASP ASP GLU ALA GLU HET 99B A1225 37 HET 99B B1225 37 HETNAM 99B 5-[(2R)-BUTAN-2-YLAMINO]-N-{(3-ENDO)-8-[5- HETNAM 2 99B (CYCLOPROPYLCARBONYL)PYRIDIN-2-YL]-8- HETNAM 3 99B AZABICYCLO[3.2.1]OCT-3-YL}-2-METHYLBENZENE-1,4- HETNAM 4 99B DICARBOXAMIDE FORMUL 3 99B 2(C29 H37 N5 O3) FORMUL 4 HOH *272(H2 O) HELIX 1 1 GLN A 23 ASN A 35 1 13 HELIX 2 2 GLU A 42 ASP A 66 1 25 HELIX 3 3 PRO A 67 ASP A 71 5 5 HELIX 4 4 THR A 99 ASN A 106 1 8 HELIX 5 5 ALA A 111 GLN A 123 1 13 HELIX 6 6 ASP A 127 GLY A 132 5 6 HELIX 7 7 VAL A 136 LEU A 143 5 8 HELIX 8 8 GLU A 192 LEU A 198 5 7 HELIX 9 9 GLU A 199 SER A 211 1 13 HELIX 10 10 GLN B 23 THR B 36 1 14 HELIX 11 11 GLU B 42 LEU B 64 1 23 HELIX 12 12 ASP B 66 ASP B 71 5 6 HELIX 13 13 THR B 99 ASN B 106 1 8 HELIX 14 14 ALA B 111 GLN B 123 1 13 HELIX 15 15 ASP B 127 GLN B 133 5 7 HELIX 16 16 VAL B 136 LEU B 143 5 8 HELIX 17 17 GLU B 192 LEU B 198 5 7 HELIX 18 18 GLU B 199 SER B 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SHEET 1 BA 8 GLU B 18 ALA B 21 0 SHEET 2 BA 8 SER B 169 THR B 174 -1 O PHE B 170 N PHE B 20 SHEET 3 BA 8 TYR B 160 SER B 164 -1 O ALA B 161 N ARG B 173 SHEET 4 BA 8 ALA B 145 LYS B 153 -1 O VAL B 148 N SER B 164 SHEET 5 BA 8 GLY B 183 LEU B 190 -1 O GLY B 183 N LYS B 153 SHEET 6 BA 8 THR B 88 ASP B 93 -1 O LEU B 89 N LEU B 188 SHEET 7 BA 8 ILE B 78 ASN B 83 -1 O ASN B 79 N VAL B 92 SHEET 8 BA 8 ILE B 218 LEU B 220 1 O THR B 219 N LEU B 80 SITE 1 AC1 19 ALA A 21 PHE A 22 GLN A 23 ASN A 51 SITE 2 AC1 19 SER A 52 ALA A 55 ASP A 93 MET A 98 SITE 3 AC1 19 LEU A 103 ILE A 104 ASN A 105 ASN A 106 SITE 4 AC1 19 LEU A 107 PHE A 138 TYR A 139 TRP A 162 SITE 5 AC1 19 PHE A 170 HOH A2029 HOH A2080 SITE 1 AC2 21 LYS A 224 ALA B 21 PHE B 22 GLN B 23 SITE 2 AC2 21 ASN B 51 SER B 52 ALA B 55 ASP B 93 SITE 3 AC2 21 MET B 98 LEU B 103 ILE B 104 ASN B 105 SITE 4 AC2 21 ASN B 106 LEU B 107 ILE B 110 PHE B 138 SITE 5 AC2 21 TYR B 139 TRP B 162 PHE B 170 HOH B2020 SITE 6 AC2 21 HOH B2057 CRYST1 44.656 57.363 57.442 70.87 87.86 68.95 P 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.022393 -0.008618 0.002196 0.00000 SCALE2 0.000000 0.018679 -0.006686 0.00000 SCALE3 0.000000 0.000000 0.018503 0.00000